Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 25

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

HER2 positive breast cancer

Recruiting

Testing 68Ga-NOTA-ABSCINT-HER2 Imaging to Predict Treatment Response in Patients with HER2-Positive Early Breast Cancer Receiving Chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:68GA-NOTA-abscint-HER2
  • Sponsor:Centre Henri Becquerel

Hormone-refractory prostate cancer

Recruiting

A Study to Find a Safe Dose of TD001 for Patients with Metastatic Castration-Resistant Prostate Cancer that Expresses PSMA

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:T.O.A.D. Oncology S.A.

Squamous cell carcinoma of skin

Recruiting

A study of onfekafusp alfa and bifikafusp alfa injected into tumors for patients with advanced skin squamous cell cancer who did not respond to or could not tolerate previous treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Basal cell carcinoma

Recruiting

Study of bifikafusp alfa and onfekafusp alfa injected into tumors for patients with locally advanced basal cell carcinoma who progressed on or cannot tolerate systemic treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Basal cell carcinoma

Recruiting

Testing bifikafusp alfa and onfekafusp alfa injections in patients with locally advanced basal cell carcinoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Colorectal cancer

Recruiting

Study of Recovery After Surgery for Colorectal Cancer Using Lidocaine and Ropivacaine in Patients Undergoing Laparoscopic Colorectal Cancer Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Endometrial cancer+6

Recruiting

A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:BioNTech SE

Adenocarcinoma pancreas+1

Recruiting

A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Institut Gustave Roussy

Adenocarcinoma pancreas

Recruiting

A Study of Olaparib Maintenance Treatment for Patients with Metastatic Pancreatic Cancer That Responded to First-Line Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Universita' Degli Studi Di Verona

Myelofibrosis

Recruiting

A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Grupo Espanol De Enfermedades Mieloproliferativas Cronicas Ph

Squamous cell carcinoma of head and neck

Recruiting

Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Transitional cell carcinoma metastatic

Recruiting

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.